No Easy Answers for Biotech Firms That Ask Why Specifications Must Diverge Globally
This article was originally published in The Gold Sheet
Executive Summary
Regulatory authorities are not uniformly sympathetic to biotechnology firms vexed by the increasingly divergent sets of specifications that are multiplying around the world for their products.